ABEO Quote, Financials, Valuation and Earnings

Celldex Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -7753.43%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 323.88%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Abeona Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.18x while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 658.38x versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of 84.08%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 323.88%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 411.63%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Abeona Therapeutics, Inc..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.18x while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 658.38x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -735.19%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 323.88%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 130.31%. Given that Abeona Therapeutics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Intellia Therapeutics, Inc..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.18x while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 658.38x versus 17.75x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of 7.29%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 323.88%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Abeona Therapeutics, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Abeona Therapeutics, Inc. is more attractive than Phibro Animal Health Corp..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.18x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 658.38x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.